These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35645119)

  • 1. Golgi phosphoprotein 3 promotes ovarian cancer progression and is associated with cisplatin resistance.
    Liu T; Jin ZW; Li Y; Zhang G; Yang XY; Xu XM; Ma YC
    J Cancer Res Ther; 2022 Apr; 18(2):488-495. PubMed ID: 35645119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
    Ma N; Zhao Y
    Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
    Yang H; Li H; Lu S; Shan S; Guo Y
    Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J; Liu L; Ling Y; Zheng J
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.
    Wang X; Jiang L; Liu Q
    J Transl Med; 2022 Jun; 20(1):258. PubMed ID: 35672774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
    Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
    Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
    Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
    J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K/AKT/mTOR signaling pathway.
    Yang N; Qu YJ; Cheng Y; Liang T; Zhang MN; Zhang D; Dong LN; Wang XW; Zhang GM
    Cancer Biomark; 2017 Jul; 19(3):263-269. PubMed ID: 28453460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy.
    Zhang M; Yue H; Huang X; Wang J; Li Z; Deng X
    ACS Appl Mater Interfaces; 2022 Nov; 14(43):48502-48514. PubMed ID: 36261925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway.
    Cui S
    J Clin Lab Anal; 2022 Dec; 36(12):e24761. PubMed ID: 36336887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.
    Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
    J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.
    Zheng YZ; Liang L
    Ann Diagn Pathol; 2018 Jun; 34():161-165. PubMed ID: 29661721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.